Resultados de búsqueda - Hawthorne, Thomas
- Mostrando 1 - 14 Resultados de 14
-
1
Chemical inhibition of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) by GSK2830371 potentiates the sensitivity to MDM2 inhibitors in a p53-dependent manner por Esfandiari, Arman, Hawthorne, Thomas A., Nakjang, Sirintra, Lunec, John
Publicado 2016Texto -
2
Initial Testing (Stage 1) of Glembatumumab Vedotin (CDX-011) by the Pediatric Preclinical Testing Program por Kolb, E. Anders, Gorlick, Richard, Billups, Catherine A., Hawthorne, Thomas, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Publicado 2014Texto -
3
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma por McGregor, Bradley A., Gordon, Michael, Flippot, Ronan, Agarwal, Neeraj, George, Saby, Quinn, David I., Rogalski, Mark, Hawthorne, Thomas, Keler, Tibor, Choueiri, Toni K.
Publicado 2020Texto -
4
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma por Duvvuri, Umamaheswar, George, Jonathan, Kim, Seungwon, Alvarado, Diego, Neumeister, Veronique, Chenna, Ahmed, Gedrich, Richard, Hawthorne, Thomas, LaVallee, Theresa, Grandis, Jennifer R., Bauman, Julie E.
Publicado 2019Texto -
5
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies por Ansell, Stephen M., Flinn, Ian, Taylor, Matthew H., Sikic, Branimir I., Brody, Joshua, Nemunaitis, John, Feldman, Andrew, Hawthorne, Thomas R., Rawls, Tracey, Keler, Tibor, Yellin, Michael J.
Publicado 2020Texto -
6
MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB por Rose, April A. N., Annis, Matthew G., Frederick, Dennie T., Biondini, Marco, Dong, Zhifeng, Kwong, Lawrence, Chin, Lynda, Keler, Tibor, Hawthorne, Thomas, Watson, Ian R., Flaherty, Keith T., Siegel, Peter M.
Publicado 2016Texto -
7
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent por Marquez-Nostra, Bernadette V., Lee, Supum, Laforest, Richard, Vitale, Laura, Nie, Xingyu, Hyrc, Krzysztof, Keler, Tibor, Hawthorne, Thomas, Hoog, Jeremy, Li, Shunqiang, Dehdashti, Farrokh, Ma, Cynthia X., Lapi, Suzanne E.
Publicado 2017Texto -
8
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma por Ott, Patrick A., Hamid, Omid, Pavlick, Anna C., Kluger, Harriet, Kim, Kevin B., Boasberg, Peter D., Simantov, Ronit, Crowley, Elizabeth, Green, Jennifer A., Hawthorne, Thomas, Davis, Thomas A., Sznol, Mario, Hwu, Patrick
Publicado 2014Texto -
9
IT-30 ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA por Reardon, David, Schuster, James, Tran, David, Fink, Karen, Nabors, Louis, Li, Gordon, Lukas, Rimas, Desjardins, Annick, Ashby, Lynn, Duic, J. Paul, Aneiro, Lynn, Hawthorne, Thomas, Green, Jennifer, Yellin, Michael, Davis, Thomas, Sampson, John
Publicado 2014Texto -
10
Phase 2 Trial of the GPNMB-Targeted Antibody-Drug Conjugate, Glembatumumab Vedotin (CDX-011) in Recurrent Osteosarcoma AOST1521: A Report from the Children’s Oncology Group (COG) por Kopp, Lisa M., Malempati, Suman, Krailo, Mark, Gao, Yun, Buxton, Allen, Weigel, Brenda J., Hawthorne, Thomas, Crowley, Elizabeth, Moscow, Jeffrey A., Reid, Joel M., Villalobos, Victor, Randall, R. Lor, Gorlick, Richard, Janeway, Katherine A.
Publicado 2019Texto -
11
Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers por Anandasabapathy, Niroshana, Breton, Gaëlle, Hurley, Arlene, Caskey, Marina, Trumpfheller, Christine, Sarma, Popi, Pring, James, Pack, Maggi, Buckley, Noreen, Matei, Irina, Lyden, David, Green, Jennifer, Hawthorne, Thomas, Marsh, Henry C., Yellin, Michael, Davis, Thomas, Keler, Tibor, Schlesinger, Sarah J.
Publicado 2015Texto -
12
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study por Vahdat, Linda T., Schmid, Peter, Forero-Torres, Andres, Blackwell, Kimberly, Telli, Melinda L., Melisko, Michelle, Möbus, Volker, Cortes, Javier, Montero, Alberto J., Ma, Cynthia, Nanda, Rita, Wright, Gail S., He, Yi, Hawthorne, Thomas, Bagley, Rebecca G., Halim, Abdel-Baset, Turner, Christopher D., Yardley, Denise A.
Publicado 2021Texto -
13
3BNC117 a Broadly Neutralizing Antibody Suppresses Viremia in HIV-1-Infected Humans por Caskey, Marina, Klein, Florian, Lorenzi, Julio C. C., Seaman, Michael S., West, Anthony P., Buckley, Noreen, Kremer, Gisela, Nogueira, Lilian, Braunschweig, Malte, Scheid, Johannes F., Horwitz, Joshua A., Shimeliovich, Irina, Ben Avraham-Shulman, Sivan, Witmer-Pack, Maggi, Platten, Martin, Lehmann, Clara, Burke, Leah A., Hawthorne, Thomas, Gorelick, Robert J., Walker, Bruce D., Keler, Tibor, Gulick, Roy M., Fätkenheuer, Gerd, Schlesinger, Sarah J., Nussenzweig, Michel C.
Publicado 2015Texto -
14
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption por Scheid, Johannes F., Horwitz, Joshua A., Bar-On, Yotam, Kreider, Edward F., Lu, Ching-Lan, Lorenzi, Julio C. C., Feldmann, Anna, Braunschweig, Malte, Nogueira, Lilian, Oliveira, Thiago, Shimeliovich, Irina, Patel, Roshni, Burke, Leah, Cohen, Yehuda Z., Hadrigan, Sonya, Settler, Allison, Witmer-Pack, Maggi, West, Anthony P., Juelg, Boris, Keler, Tibor, Hawthorne, Thomas, Zingman, Barry, Gulick, Roy M., Pfeifer, Nico, Learn, Gerald H., Seaman, Michael S., Bjorkman, Pamela J., Klein, Florian, Schlesinger, Sarah J., Walker, Bruce D., Hahn, Beatrice H., Nussenzweig, Michel C., Caskey, Marina
Publicado 2016Texto